• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

inflammatory diseases

Alert
Pharma

FDA rejection letters flag data concerns for AZ, GSK biologics

The FDA cited “critical data quality issues” in rejecting AZ's Saphnelo for SLE, and it ruled that GSK's Exdensur lacked “adequate evidence” in CRSwNP.
Angus Liu Mar 3, 2026 11:30am
business growth strategy

Upside for Insmed after Brinsupri’s first-in-class sales beat

Jan 9, 2026 10:40am
GSK London

GSK scoops up yet another FDA approval, this time in asthma

Dec 17, 2025 8:30am
Traffic light go start restart green light

GSK's long-acting asthma med wins CHMP backing

Dec 12, 2025 11:27am
On target clinical trial success bullseye score

Alfasigma's JAK inhibitor Jyseleca scores in phase 3 trial

Jul 29, 2025 8:50am
Missed target failed trial trial failure

InflaRx scraps vilobelimab study in rare skin disorder

May 28, 2025 9:55am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings